CUSIP: 85858C107
Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
19,860,266
-
Share change
-
-432,601
-
Total reported value
-
$329,675,718
-
Put/Call ratio
-
1510%
-
Price per share
-
$16.60
-
Number of holders
-
88
-
Value change
-
-$7,090,437
-
Number of buys
-
41
-
Number of sells
-
33
Quarterly Holders Quick Answers
What is CUSIP 85858C107?
CUSIP 85858C107 identifies STML - STEMLINE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2018
-
Previous quarter:
Q2 2018
Recent filing periods for CUSIP 85858C107:
Institutional Holders of STEMLINE THERAPEUTICS INC - COM (STML) as of Q3 2018
As of 30 Sep 2018,
STEMLINE THERAPEUTICS INC - COM (STML) was held by
88 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,860,266 shares.
The largest 10 holders included
Consonance Capital Management LP, Polar Capital LLP, BlackRock Inc., FMR LLC, Lyon Street Capital, LLC, Vanguard Group Inc, EVENTIDE ASSET MANAGEMENT, LLC, CITADEL ADVISORS LLC, STATE STREET CORP, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
88
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.